Thanks for being part of this project. Click here to see all our collaborators.

Collabotate with Marsi Bionics to help children rehabilitate through gait exoskeletons

If you have ever wanted to be a part of a project involving groundbreaking technology, as well as worldwide social relevance, this is your opportunity. In addition, you have a chance to become a partner in the project and benefit economically from its result. In order for all of this to happen we have started this crowdfunding campaign.

The project

Marsi Bionics is a business project that seeks to transfer to society the results obtained through research into pediatric exoskeletons. Marsi Bionics owns the only pediatric wearable gait exoskeleton, which has been already clinicaly tested on a number of children with success. Thousands of children all around the world are waiting for this device to help improve their quality of life and life expectancy. For them, time is critical. The current barrier to commercialization is the investment required for industrialization and certification of the exoskeleton as medical device. At the present time we lack seed money that would allow us to start this process.

Exoskeletons are medical products, and thus have to adhere to security, risk and electromagnetic compatibility regulations. In order to certify that our exoskeletons pass regulatory requirements it is necessary to put them through industrial manufacturing processes, do risk and security testing, including tests, and finally test again the commercial product in a clinical setting. The entire process will require an investment of close to 1,5 million euros.

This crowdfunding campaign is vital, if we raise the funding needed for certifications we can put the exoskeleton in the market in one year from now. A very small contribution from thousand people can give hope and life to 17 million children in the world. Please donate!

Pediatric exoskeletons

The product that Marsi Bionics wishes to commercialize is a bionic gait exoskeleton, a robot that is attached to the body and legs of a child that is unable to walk. The exoskeleton will allow the child to walk and do day to day activities on their own, and so have a large impact both on their health and their quality of life.

Health impact:

Permanent sedentarism leads to physiological degeneration in the child, including scoliosis, osteoporosis, muscle spasms, regressions, respiratory problems and circulatory problems that worsen the health of the child and threaten their lives. Walking is vital to prevent these complications. Walking exoskeletons serve this purpose.

Impact on quality of life:

Children are social by nature and they need to integrate socially in order to have a proper development. Wheelchairs limit this integration, and also prevent the development of autonomy, as the child relies on their mother or father for day to day physical activities. Changing the wheelchair for a walking exoskeleton will have a tremendous psychological impact on the child, allowing them independence that will allow them to integrate socially and benefit their self-esteem, and so help them in their personal development.

This technology is protected by three patents:

  1. P201231567 (11/10/2012); PCT/ES2013/070689 (07/10/2013). Regional phases USA (14/434,817) and Europe (13845354.3).
  2. P201330882 (13/06/2013) PCT/ES2014/070422 (23/05/2014)
  3. P201431763 (27/11/2014)

The competitive advantage of Marsi Bionics is the ability to self-adapt the exoskeleton to the symptoms of the patient, thus expanding the range of potential users, as well as the ability to adapt to different terrain, which expands the usability of the units outside the hospital setting. This new technology has received 8 innovation awards from different scientific and technological institutions including IEEE, Elsevier, Clawar association and euRobotics Asbl.

Marsi Bionics has also recieved the madri+d prize for best technological business idea, the second Price in the European Robotics Investment Forum, pasion>ie first prize for businesses offering “Health of the Future” (IE Business School + Accenture) and first prize INNOVAeVia (eVia-AMETIC), among others.

Our mission is global

Our pediatric exoskeleton has been tested in children from 3 to 9 years old with Spinal Muscular Atrophy in close cooperation with Sant Joan de Déu Childrens Hospital (Barcelona, Spain) and University Hospital Ramon y Cajal (Madrid, Spain). Current results validate the usability of the exoskeleton.  Marsi Bionics is the only company in the world that developes pediatric gait exoskeletons for neuromuscular diseases, cerebral palsy, spina bifida and more.

So that families will have access to this expensive technology, our business model is one based on rental co-pays, so that National Health Systems will give covarage to the therapeutical use of the exoskeleton. Units will grow with the child and so size adjustments will be part of routine maintenance.

This is a unique website which will require a more modern browser to work! Please upgrade today!